On this page
What are exosomes?
Exosomes are very small extracellular vesicles released by cells as part of communication with other cells. They may carry proteins, lipids and molecules conveying genetic messages. Interest in skin applications relates to possible effects on tissue repair and cellular responses.
They should not be regarded as an established standard treatment with fully predictable outcomes. Human studies are increasing, but products, routes and assessment methods differ considerably.
Exosomes are not stem cells
An exosome is not a cell: it cannot multiply or turn into another cell. Different cells, including stem cells, can release exosomes, but this does not mean that a resulting product contains living stem cells.
The term alone does not describe every marketed product. Some focus on purified extracellular vesicles, others contain cell-culture medium, and some combine vesicles with hyaluronic acid, amino acids, peptides, vitamins or other ingredients.
Different product groups
- Mesenchymal-cell-derived: cultures originating from tissues such as fat, bone marrow or umbilical cord may be used. Manufacturing conditions influence contents even with a similar source.
- Platelet-derived: products developed from platelet-released extracellular vesicles are not the same as PRP made from your own blood.
- Animal-derived: vesicles from bovine milk and particularly colostrum are being studied. Much of the skin-repair evidence is laboratory or animal research and cannot be equated directly with human-derived products or aesthetic injection outcomes.
- Plant-derived: these particles are more accurately described as exosome-like nanovesicles and should not be considered biologically identical to human or animal exosomes.
- Conditioned culture medium: this may contain vesicles alongside soluble proteins and other secreted products; it is not synonymous with isolated, purified exosomes.
- Combined formulations: added hyaluronic acid, amino acids, peptides, vitamins or antioxidants mean that the whole formula must be assessed rather than attributing every effect to exosomes.
What distinguishes products?
Source is only the starting point. Culture conditions, separation methods, particle count, purity, residual proteins, sterility, storage and cold-chain handling also matter.
In combination formulas, the structure and quantity of hyaluronic acid, other ingredients and their compatibility for injection require assessment. It is not always possible to distinguish vesicle-related changes from carrier or added-ingredient effects.
I consider traceability, analytical documentation, suitability of the whole formula for injection, the recommended route and storage conditions. A product should not be assumed suitable for intradermal injection when these are unclear.
How I apply them at my practice
I use direct injection of products whose suitability for injection has been verified, distributing small amounts into the selected areas and appropriate tissue plane.
This differs from applying a product on the skin after microneedling. An “exosome” label alone does not establish suitability for injection; the route must be checked for the specific product.
Which concerns may be considered?
Skin texture, dullness, fine lines, and the appearance of hydration and elasticity on the face and neck may be discussed. This does not replace filler for substantial volume loss, botulinum toxin for strong expression lines, or adequately address advanced laxity by itself.
Dryness and uneven texture may have different causes. Suitability for the intended change matters more than popularity.
When should the effect be assessed?
Early swelling or brightness can be a temporary injection effect. Published clinical studies commonly assess appearance at four to eight weeks, sometimes following participants to 12 weeks.
A universally applicable onset or duration for direct injection across products has not been established. Consistent lighting and an appropriate review interval are preferable to judging early swelling.
What I assess at the first consultation
- Skin needs: texture, sensitivity, dryness, active disease and expectations.
- Health: allergies, immune-related conditions, medicines and previous procedures.
- Product characteristics: source, composition, sterility, storage and verified suitability for direct injection.
Treatment and aftercare
After cleansing, fine needles deliver the preparation at planned sites. Small bumps, redness, tenderness, mild swelling or bruising may occur and often decrease over one to three days.
Initially avoid irritating skincare and intense heat, keep the area clean and follow individual advice. Increasing pain, warmth, marked redness or an unexpected reaction require contact with the practice.
Evidence and product safety
Early clinical findings are promising, but stronger human studies are needed for long-term safety, optimal dosing and standardised protocols. Injection data must be distinguished from topical or post-device data.
Source, purity, sterility, storage chain and intended route must be clear. Regulatory status varies between countries, so current product documentation is checked before treatment.
Frequently asked questions
Are exosomes stem cells?
No. They are extracellular vesicles involved in cellular communication, not cells capable of multiplying or becoming new tissue.
Are all products equivalent?
No. Source, culture conditions, purification, concentration, added ingredients, sterility and storage may differ.
What types are available?
Sources and preparations include mesenchymal stromal cell cultures, platelets, animal-derived vesicles and plant-derived exosome-like particles. Culture media and combined formulations are distinct from purified exosomes.
When is the outcome assessed?
Studies often use four to eight weeks, sometimes 12 weeks. Early swelling is not the final result, and a universal onset or duration for direct injection is not established.
How many sessions are needed?
There is no accepted universal schedule. Verified product instructions, baseline condition and response guide planning. Reviewing an initial response at an appropriate four-to-eight-week interval may be more useful than unnecessary early repetition.
Why direct injection?
It delivers small amounts into selected areas and tissue planes. Only products with verified injection suitability and instructions should be considered for this route.
Can it be planned with RF microneedling, PRP or mesotherapy?
Sometimes these form different stages of a skin plan. They need not be performed together; sequence and spacing depend on skin needs, products and healing.
